Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
ID: 347228Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347228

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-153.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)" aimed at investigating the effects of climate change on cancer risks, prevention, and survivorship. This initiative seeks innovative research that explores various aspects of the relationship between climate-related environmental changes and cancer, emphasizing the need for multidisciplinary collaboration among researchers with expertise in climate change. The program supports both new and renewal applications for a maximum project period of five years, with no strict budget limitations, and encourages participation from institutions serving underrepresented populations. Interested applicants can find more information and application details at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-153-Full-Announcement.html
    PAR-23-153.html
    The funding opportunity from the National Institutes of Health (NIH) aims to investigate the impacts of climate change across the cancer control continuum. The initiative seeks innovative research to understand how climate change affects cancer risks, prevention, survivorship, and concludes that it necessitates multidisciplinary collaboration involving researchers with climate change expertise. Applications may cover a diverse range of research topics, such as the relationship between climate-related environmental changes and cancer risk, the vulnerability of cancer survivors to climate-induced health effects, and strategies to enhance equitable cancer care in light of climate disruptions. The funding supports both new and renewal applications, with a maximum project period of five years and no strict budget limitation. This program encourages participation from various institutions, with a particular emphasis on institutions serving underrepresented populations. The application process requires adherence to specific instructions and compliance with eligibility criteria. This opportunity emphasizes the growing concern about climate change's effects on public health and the crucial need for targeted research and strategies to mitigate its adverse consequences on cancer care and health equity.
    Similar Opportunities
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity focused on the impacts of climate change across the cancer control continuum, designated as the R01 Clinical Trial Optional grant. This initiative aims to support innovative research that assesses the effects of climate-related changes on cancer risks, prevention, survivorship, and healthcare delivery, with an emphasis on developing interventions to address health disparities and enhancing climate-resilient healthcare systems. The funding opportunity is critical for advancing understanding in this area and promoting multidisciplinary research to tackle significant challenges in cancer care exacerbated by environmental changes. Interested applicants, including higher education institutions, non-profits, and various government entities, must submit their applications by May 7, 2026, and can find additional details and guidelines at the provided NIH link or by contacting grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)" aimed at fostering innovative research on the intersection of climate change and cancer. This R21 Exploratory/Developmental Research Grant seeks to explore various aspects of cancer risks exacerbated by climate change, including environmental influences, healthcare disruptions, and health disparities, with a focus on multidisciplinary approaches and collaboration with climate change experts. The grant supports studies with budgets up to $275,000 over a two-year period, and eligible applicants include higher education institutions, nonprofits, state and local governments, and for-profit organizations. Interested parties should note that the application deadline is May 7, 2026, and can find more information at the provided link or contact NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)." This initiative aims to support applications that propose secondary data analysis and integration of existing datasets to better understand cancer risk factors and related outcomes, including survival and treatment responses. The program emphasizes the importance of leveraging clinical, genomic, lifestyle, and environmental data to address significant scientific questions in cancer research. Interested applicants can apply for grants with a maximum budget of $350,000 per year, with a project duration of up to five years. The application deadline is September 7, 2026, and further details can be obtained by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.